In the OASIS 4 trial, the tablet produced an average weight loss of 13.6% over 64 weeks, broadly the same as the 2.4 mg injection and less than Mounjaro or the 7.2 mg injection
Tirzepatide, on the other hand, is a dual agonist, targeting both the GLP-1 and GIP receptors, offering enhanced glucose control and weight loss by combining the effects of both incretin hormones
Below is your guide to know the red flags those symptoms that dont go away and may need your doctors intervention
Key Takeaways Semaglutide mimics GLP-1 to slow digestion, reduce appetite, and support lasting fullness for weight management
Semaglutide peptide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist referenced in peptide chemistry, molecular biology, and metabolic research literature